| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.29 | 7e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.26 | 4e-06 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.34 | 4e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.21 | 7e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0006 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.16 | 0.0009 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0009 |